NTLA Stock Summary and Trading Ideas (Intellia Therapeutics | NASDAQ:NTLA)

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics trades on the NASDAQ stock market under the symbol NTLA.

As of March 13, 2026, NTLA stock price declined to $12.71 with 1,422,869 million shares trading.

NTLA has a beta of 1.76, meaning it tends to be more sensitive to market movements. NTLA has a correlation of 0.08 to the broad based SPY ETF.

NTLA has a market cap of $1.47 billion. This is considered a Small Cap stock.

Last quarter Intellia Therapeutics reported $23 million in Revenue and -$.83 earnings per share. This beat revenue expectation by $11 million and exceeded earnings estimates by $.14.

In the last 3 years, NTLA traded as high as $47.48 and as low as $5.90.

The top ETF exchange traded funds that NTLA belongs to (by Net Assets): ARKK, VTI, XBI, ARKG, VB.

NTLA has outperformed the market in the last year with a return of +32.1%, while the SPY ETF gained +20.2%. In the last 3 month period, NTLA beat the market returning +40.9%, while SPY returned -2.2%. However, in the most recent 2 weeks NTLA has underperformed the stock market by returning -11.0%, while SPY returned -3.6%.

NTLA support price is $12.20 and resistance is $13.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NTLA shares will trade within this expected range on the day.